Cell cycle and anti-estrogen effects synergize to regulate cell proliferation and ER target gene expression

Area of Science:

• Endocrinology
• Molecular Biology
• Oncology

Background:

• Antiestrogens like OH-Tamoxifen and Fulvestrant inhibit hormone-driven proliferation and gene expression in breast cancer.
• Current understanding primarily focuses on antiestrogen effects in the G0/G1 cell cycle phase.

Purpose of the Study:

• To investigate the direct impact of cell cycle stage on estrogen receptor (ERalpha) regulated gene expression.
• To determine if cell cycle progression influences the efficacy of antiestrogen therapies.

Main Methods:

• Utilized ERalpha-positive MCF-7 breast cancer cells.
• Analyzed ERalpha and target gene expression across different cell cycle phases.
• Assessed antiestrogen effects on gene transcription in synchronized cell cycle populations.

Main Results:

• ERalpha and target gene expression exhibit significant cell cycle regulation (up to three-fold variation).
• Steroid-free conditions, often used experimentally, lead to G1-phase arrest with overexpression of some ERalpha target genes.
• Antiestrogens specifically repress ERalpha target gene transcription during the S phase of the cell cycle.
• This S-phase specific repression correlates with enhanced antiestrogen effects on proliferation and increased apoptosis.

Conclusions:

• Cell cycle stage is a critical factor influencing ERalpha target gene expression and antiestrogen efficacy.
• Cell cycle-dependent effects synergize with antiestrogen actions.
• Combining antiestrogen therapy with cell cycle-specific drugs presents a promising therapeutic strategy to enhance treatment outcomes in breast cancer.